Mustang Bio Announces Updated Interim Phase 1/2 Data for MB-106 in Patients with Relapsed or Refractory B-cell Non-Hodgkin Lymphoma and Chronic Lymphocytic Leukemia
Stock Information for Fortress Biotech Inc.
Loading
Please wait while we load your information from QuoteMedia.